Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Recruiting now · Phase 4

Conditions studied: Psoriasis

In brief

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Key facts

Study ID

NCT03827876

Run by

Psoriasis Treatment Center of Central New Jersey

People needed

30

Starts

2019-01-16

Expected to finish

2019-12-15

Last updated by the study team

2019-02-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female adult ≥ 18 years of age;
• Diagnosis of chronic plaque-type
• Patient with 2-10% BSA
• Physician Global Assessment of 2 or greater
• Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks

You may not qualify if…

• ˂2 or >10% BSA
• PGA <2
• Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab <24weeks

Where it is running

• Psoriasis Treatment Center of Central New Jersey — East Windsor, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.